A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma
NK/T-cell lymphoma (NKTCL) is a rare type of non-Hodgkin lymphoma (NHL). Although L-asparaginase-based chemotherapy has significantly improved survival in early-stage patients, the prognosis is poor in advanced and relapsed or refractory patients. CD47 is a promising target for cancer immunotherapy....
| Prif Awduron: | , , , , , , |
|---|---|
| Fformat: | Erthygl |
| Iaith: | English |
| Cyhoeddwyd: |
Taylor & Francis Group
2024-12-01
|
| Cyfres: | Human Vaccines & Immunotherapeutics |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2408088 |